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Abstract
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous 
thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to 
study the effect of liraglutide intervention on markers of VTE and CVD risk, in PCOS. 
In a double-blind, placebo-controlled, randomized trial, 72 overweight and/or insulin-
resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 
1.8 mg/day. Endpoints included between-group difference in change (baseline to 
follow-up) in plasminogen activator inhibitor-1 levels and in thrombin generation 
test parameters: endogenous thrombin potential, peak thrombin concentration, lag 
time and time to peak. Mean weight loss was 5.2 kg (95% CI 3.0–7.5 kg, P < 0.001) in 
the liraglutide group compared with placebo. We detected no effect on endogenous 
thrombin potential in either group. In the liraglutide group, peak thrombin 
concentration decreased by 16.71 nmol/L (95% CI 2.32–31.11, P < 0.05) and lag time and 
time to peak increased by 0.13 min (95% CI 0.01–0.25, P < 0.05) and 0.38 min  
(95% CI 0.09–0.68, P < 0.05), respectively, but there were no between-group differences. 
There was a trend toward 12% (95% CI 0–23, P = 0.05) decreased plasminogen activator 
inhibitor-1 in the liraglutide group, and there was a trend toward 16% (95% CI 
−4 to 32, P = 0.10) reduction, compared with placebo. In overweight women with PCOS, 
liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide 
affected thrombin generation, although not significantly differently from placebo. 
A concomitant trend toward improved fibrinolysis indicates a possible reduction of 
the baseline thrombogenic potential. The findings point toward beneficial effects of 
liraglutide on markers of VTE and CVD risk, which should be further pursued in larger 
studies.
Introduction
With a prevalence of 10%, polycystic ovary syndrome 
(PCOS) is the most common endocrine disorder among 
women of fertile age (1). The diagnosis is based on the three 
Rotterdam criteria: oligo-/amenorrhea, androgen excess 
and polycystic ovaries, where a minimum of two should be 
fulfilled and other etiologies excluded (2). The Rotterdam 
criteria encompass an ovarian dysfunction, but it is evident 
that PCOS also has a metabolic component, covering 
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abdominal obesity, hypertension and dyslipidemia, as 
well as insulin resistance (3). The abdominal obesity 
is characterized by a state of low-grade inflammation. 
Visceral adipose tissue secretes pro-inflammatory 
adipokines promoting an inflammatory state, contributing 
to endothelial dysfunction, which is associated with an 
increased risk of cardiovascular disease (CVD) (4).
PCOS is associated with both CVD and venous 
thromboembolism (VTE). A recent meta-analysis found 
an odds ratio of 1.44 (1.13–1.84) for coronary heart 
disease in women with PCOS vs non-PCOS (5) and 
a cohort study, which included 87,000 participants, 
found 1.5-fold higher risk for VTE in women with 
PCOS than in controls (6). In general, cardiovascular 
events are rare in premenopausal women, which is why 
markers of low-grade inflammation and endothelial 
dysfunction are often used as measures of CVD risk in 
interventional studies in PCOS. Due to their association 
with atherosclerotic CVD, levels of von Willebrand 
factor (vWF), plasminogen activator inhibitor 1 (PAI-1) 
and high-sensitivity-CRP (hsCRP) are frequently used 
as surrogate CVD risk markers (7, 8, 9) and they are all 
found to be elevated in PCOS (10, 11).
Elevated thrombin generation, as measured by 
thrombin generation test, indicates hypercoagulability, 
as seen in users of combined oral contraceptives (12). 
Moreover, high thrombin generation is associated with 
first and recurrent VTE and possibly with coronary 
atherosclerosis (13, 14, 15). Thrombin generation has 
been found to be elevated in PCOS (12), but conflicting 
data exist (16). In a previous study, our group found high 
thrombin generation, PAI-1 and hsCRP to be linked to 
the overweight and insulin-resistant PCOS phenotype 
(17, 18). Thrombin generation seems to mainly be 
driven by overweight (19, 20) and is found to diminish 
with weight loss (21, 22, 23). The increased thrombin 
generation, together with hypofibrinolysis, as measured 
by elevated PAI-1 levels, could be a link to the increased 
risk of VTE in PCOS.
Lifestyle intervention and metformin are mainstays 
in the treatment of PCOS, aiming at reducing body weight 
and insulin resistance. In women with PCOS, metformin 
has been found to reduce PAI-1 activity and levels of hsCRP 
to a mild degree (24) and might to some extent diminish 
the increased thrombin generation induced by oral 
contraceptives, as recently investigated (12). Glucagonlike 
peptide-1 (GLP-1) analogs are commonly used in type 2 
diabetes and obesity, where they promote weight loss, 
improve glycemic control and have been demonstrated 
to reduce plasma levels of cholesterol, PAI-1 and hsCRP 
(25, 26, 27). Glucagonlike peptide-1 analogs have been 
used in PCOS in smaller trials, all demonstrating weight 
loss, but none investigating the effect on thrombin 
generation or PAI-1 (28, 29, 30, 31, 32).
We hypothesized that intervention with the GLP-1 
analog liraglutide, in overweight women with PCOS, would 
lead to a beneficial reduction in VTE and CVD risk markers: 
thrombin generation, vWF, PAI-1 and hsCRP, possibly 
due to a weight loss. To investigate this, we performed a 
randomized clinical trial (RCT) treating women with PCOS 
with either liraglutide or placebo for 26 weeks.
Subjects and methods
A randomized, placebo-controlled, double-blind clinical 
trial was conducted from March 2014 to December 2015 
at Herlev Gentofte Hospital, University of Copenhagen, 
Denmark. Seventy-two women were randomized, in a 
2:1-ratio, to 26 weeks of intervention with liraglutide or 
placebo 1.8 mg once daily. The study is registered at www.
clinicaltrials.gov: NCT02073929.
The study was approved by the Danish Data Protection 
Agency and the Ethics Committee of the Capital Region 
of Denmark (ID: H2-2013-142, EudraCT: 2013-003862-
15) and performed in accordance with General Clinical 
Practice guidelines and the Declaration of Helsinki. 
After full explanation of the purpose and nature of all 
procedures used the participants gave oral and written 
informed consent, prior to screening.
Participants
Participants were enrolled from social media (www.
facebook.com/PCOSkliniskforsoeg), from private 
practicing gynecologists and from our outpatient 
PCOS clinic, securing external validity. Inclusion and 
exclusion criteria are published elsewhere (33). In 
short, eligible women were ≥18 years, premenopausal 
and had PCOS according to Rotterdam criteria, i.e., 
minimum two of the three (1) oligo-/amenorrhea 
(cycle >35  days), (2) clinical (Ferriman–Gallwey 
score ≥8) or biochemical hyperandrogenism 
(total or free testosterone levels above reference: 
>1.8 nmol/L and >0.034 nmol/L, respectively) and 
(3) polycystic ovaries (≥12 follicles (2–9 mm) and/or 
volume >10 mL in at least one ovary) on transvaginal 
ultrasound. Other causes to bleeding irregularities 
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and androgen excess were excluded. The women 
should have BMI ≥25 kg/m2 and/or insulin resistance 
defined as fasting plasma C-peptide >0.6 nmol/L 
at screening. In brief, exclusion criteria were 
pregnancy, breastfeeding, smoking >10 cigarettes/
day, diabetes, hypertension, overt inflammatory 
disease, use of herbal medicine or medications known 
to affect the hemostatic system. The use of hormonal 
contraceptives within six weeks, injectable hormonal 
contraceptives within six months and antidiabetic or 
antihypertensive drugs within three months prior to 
randomization led to exclusion.
Intervention, randomization and blinding
Liraglutide/placebo was administered as a subcutaneous 
injection once daily: 0.6 mg the first week, 1.2 mg the 
second week and 1.8 mg for the rest of the study period 
(26  weeks in total). This dose was chosen as it caused 
weight loss and improved glycemic control in obese 
patients with type 2 diabetes (34). The participants 
registered compliance daily in a medical diary provided 
by the study personnel. The study drug (liraglutide 
and placebo) was delivered in identical prefilled pens, 
labeled with serial numbers and accompanied by a 
randomization list. As investigators and participants 
were blinded, an independent secretary instructed the 
investigators as to which serial numbers to supply each 
woman with. The participants were randomized in a 2:1 
ratio (liraglutide:placebo), as we believed that this would 
facilitate the recruitment to the study.
Outcomes
Primary outcome was the difference between the groups 
in change from baseline to follow-up in endogenous 
thrombin potential (ETP) measured by thrombin 
generation test (TGT). Secondary outcomes were 
differences between groups in change from baseline 
to follow-up in other parameters of TGT (described in 
‘Assays’ subsection) as well as plasma levels of vWF, PAI-1 
and hsCRP.
Protocol
Each woman participated in four visits: screening, 
baseline (week 0), safety (week 8) and follow-up 
(week 26), previously described (33). At screening, 
informed consent was obtained after which a medical 
interview, physical examination, blood sample 
collection and transvaginal ultrasound were performed. 
At baseline and follow-up visits, participants had 
their blood drawn (between 08:00 and 10:00 h) after 
an overnight fast. After 15 min in a seated position, 
blood was drawn from an antecubital vein with a 
light tourniquet (40 mmHg). Blood was collected in 
citrated vacuum tubes and centrifuged for 20 min at 
2000 g after which platelet poor plasma and serum were 
stored at −80°C until analysis. Weight, waist and hip 
circumference and blood pressure were measured in a 
standardized way. At the safety visit, participants had 
a brief physical examination and routine blood work 
done. Adverse events were registered at every visit, and 
participants were instructed to contact the investigators 
if they experienced any adverse effects.
Assays
Thrombin generation was assessed with a Calibrated 
Automated Thrombogram (Thrombinoscope BV, 
Maastricht, The Netherlands) using a fluorogenic method. 
After activation of the coagulation by adding tissue 
factor and phospholipids to platelet poor plasma, four 
parameters were measured: time to start of thrombin 
generation (lag time, min); peak thrombin concentration 
(nmol/L); time to peak (min) and area under the curve 
(endogenous thrombin potential (ETP), nmol/L × min) 
(35). Intra-assay CV: 3.4–5.7% for all parameters. Plasma 
levels of vWF-antigen were determined with a particle-
enhanced immunoturbidimetric assay, HemosIL von 
Willebrand Factor Antigen kit using an ACL 9000 System 
(Instrumentation Laboratory, Milan, Italy), plasma levels 
of PAI-1 were determined with an ELISA (antibodies: 
Mon-I-1 and Mon-I-6) on Tecan Sunrise plate reader 
(Tecan, Basle, Switzerland) and plasma levels of hsCRP 
using a CardioPhase hsCRP kit on a BNII protein analyzer 
(Siemens Healthcare Diagnostics GmbH), with CV 4.6, 
6.4 and 3.1%, respectively. All analyses were performed 
at Unit for Thrombosis Research, Department of Clinical 
Biochemistry, Hospital of South West Denmark, Esbjerg, 
Denmark. Baseline and follow-up samples from each 
participant were analyzed in the same batch. Plasma 
levels of insulin were determined using an electro-
chemiluminescent immunoassay and a Cobas e411 
reader (Roche Diagnostics GmbH), with an intra-assay CV 
of 2.1%. The Homeostasis Model Assessment of insulin 
resistance (HOMA2-IR) was calculated from fasting levels 
of insulin and glucose using an online HOMA calculator 
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(www.dtu.ox.ac.uk/homacalculator). Glucose, HbA1c, 
cholesterol and triglyceride levels were assessed 
using routine analyses at the Department of Clinical 
Biochemistry, Herlev Gentofte Hospital, Denmark. 
Androgen levels were determined using liquid 
chromatography and double mass spectrometry at 
Rigshospitalet, Copenhagen, Denmark.
Statistics
A sample size calculation based on an estimated standard 
deviation of 130 units obtained from in-house data, 
declared 63 subjects, randomized 2:1, needed for 80% 
power to find a difference in effect size of 100 nmol/min 
of ETP. This effect size was supported by a previous study 
finding a similar reduction in ETP with a 5% reduction 
in BMI (22). To allow for drop-outs, 72 women were 
randomized. Distribution of data was checked using 
histograms and probability plots. Normally distributed 
data are presented as mean (s.d.), non-normally 
distributed data as median (p25–p75) and differences as 
mean (95% CI). Data were logarithmic transformed as 
appropriate, which is why some differences are presented 
as ratios. Fishers exact test was used for comparison of 
adverse effects between groups and paired t-test for 
quantification of effect (follow-up – baseline) in each 
group. In the initial protocol, we planned on calculating 
the between-group difference using an unpaired t-test on 
the intention-to-treat population. As a mixed model with 
maximum likelihood is a more optimal way of analyzing 
repeated measurements, we have chosen this statistic 
approach, and between-group differences in treatment 
effect are assessed using a repeated measurements mixed 
model (with maximum likelihood) with study drug 
as between-subjects effect and visit (time) as within-
subject effect. Baseline data from all 72 women were 
included in the mixed model analyses, and missing data 
were assumed to be missing at random. Pre-specified 
subgroup analyses for Rotterdam phenotypes as well as 
for four metabolic subgroups using median HOMA2-IR 
and BMI 25 kg/m2 as cut-offs (HOMA2 < 2.3 + BMI < 25; 
HOMA2 < 2.3 + BMI > 25; HOMA2 > 2.3 + BMI < 25 and 
HOMA2 > 2.3 + BMI > 25) were performed using Mann–
Whitney U test with Bonferroni correction. Associations 
between ETP and anthropometric, metabolic and 
endocrine parameters were assessed using univariate and 
multivariate linear regression analyses on baseline data. 
In analyses regarding hsCRP, estimates >10 mg/L were 
excluded as this indicated infection. Statistical analyses 
were performed using SAS Enterprise Guide 7.1 (SAS 
Institute Inc., Cary, NC, USA). A two-sided P value <0.05 
was considered significant.
Figure 1
Flow chart of included and excluded participants.
Screening
(n = 138)
Excluded (n = 66)
Not meeng inclusion criteria (n = 56)
Not Roerdam (n = 23)
BMI <25 or no insulin resistance (n = 29)
Other (n = 4) 
Declined to parcipate (n = 7)
Needle phobia (n = 2)
Personal reasons (n = 5)
Other (n = 3)
Analysed (n = 44)/(n = 48)
Lost to follow-up (n = 2)
Did not respond when contacted (n = 2)
Disconnued intervenon (n = 2)
Adverse effects: Abdominal pain (n = 2)
Liraglude (n = 48)
Received intervenon (n = 48)
Lost to follow-up (n = 1)
Did not respond when contacted (n = 1)
Disconnued intervenon (n = 1)
Adverse effects: Gallstone related pain (n = 1)
Placebo (n = 24)
Received intervenon (n = 23)
Withdrew consent at randomizaon day (n = 1) 
Analysed (n = 21)/(n = 24)
Randomizaon
(n = 72)
Follow-up
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group. In the initial protocol, we planned on calculating 
the between-group difference using an unpaired t-test on 
the intention-to-treat population. As a mixed model with 
maximum likelihood is a more optimal way of analyzing 
repeated measurements, we have chosen this statistic 
approach, and between-group differences in treatment 
effect are assessed using a repeated measurements mixed 
model (with maximum likelihood) with study drug 
as between-subjects effect and visit (time) as within-
subject effect. Baseline data from all 72 women were 
included in the mixed model analyses, and missing data 
were assumed to be missing at random. Pre-specified 
subgroup analyses for Rotterdam phenotypes as well as 
for four metabolic subgroups using median HOMA2-IR 
and BMI 25 kg/m2 as cut-offs (HOMA2 < 2.3 + BMI < 25; 
HOMA2 < 2.3 + BMI > 25; HOMA2 > 2.3 + BMI < 25 and 
HOMA2 > 2.3 + BMI > 25) were performed using Mann–
Whitney U test with Bonferroni correction. Associations 
between ETP and anthropometric, metabolic and 
endocrine parameters were assessed using univariate and 
multivariate linear regression analyses on baseline data. 
In analyses regarding hsCRP, estimates >10 mg/L were 
excluded as this indicated infection. Statistical analyses 
were performed using SAS Enterprise Guide 7.1 (SAS 
Institute Inc., Cary, NC, USA). A two-sided P value <0.05 
was considered significant.
Results
Participant flow, baseline data and adverse effects
Of 138 women assessed for eligibility, 72 were included 
of which 48 were randomized to liraglutide and 24 to 
placebo (Fig.  1). Groups were comparable at baseline 
(Table 1). One woman in the placebo group withdrew her 
consent before starting treatment. Dropout ratio was 7/72 
(9.7%) overall, 4/48 (8.3%) in the liraglutide and 3/24 
(12.5%) in the placebo group. In the liraglutide group, 
the most prevalent adverse effect was nausea, mainly in 
the up-titration phase (Table 2). Gallstone-related pain 
was experienced by three (6.4%) women in the liraglutide 
group and one (4.4%) in the placebo group, and two 
women in the liraglutide group had a cholecystectomy. 
Due to the discontinuation of study drug during diagnosis 
and surgery, overall compliance for the two women 
was 64% and 87%, respectively. Self-reported median 
(p25–p75) compliance was 96% (89–99) in the active 
group and 93% (87–98) in the placebo group (P = 0.70). 
In the liraglutide group 1 (2%), 7 (15%) and 38 (83%) 
women completed the study at 0.6 mg/day, 1.2 mg/day 
and 1.8 mg/day, respectively. All women in the placebo 
group completed the study at the highest dose.
Figure 1
Flow chart of included and excluded participants.
Screening
(n = 138)
Excluded (n = 66)
Not meeng inclusion criteria (n = 56)
Not Roerdam (n = 23)
BMI <25 or no insulin resistance (n = 29)
Other (n = 4) 
Declined to parcipate (n = 7)
Needle phobia (n = 2)
Personal reasons (n = 5)
Other (n = 3)
Analysed (n = 44)/(n = 48)
Lost to follow-up (n = 2)
Did not respond when contacted (n = 2)
Disconnued intervenon (n = 2)
Adverse effects: Abdominal pain (n = 2)
Liraglude (n = 48)
Received intervenon (n = 48)
Lost to follow-up (n = 1)
Did not respond when contacted (n = 1)
Disconnued intervenon (n = 1)
Adverse effects: Gallstone related pain (n = 1)
Placebo (n = 24)
Received intervenon (n = 23)
Withdrew consent at randomizaon day (n = 1) 
Analysed (n = 21)/(n = 24)
Randomizaon
(n = 72)
Follow-up
Table 1 Baseline characteristics in the 72 PCOS women randomized.
 Liraglutide (n = 48) Placebo (n = 24) P
Age (years) 31.4 (24.6–35.6) 26.2 (24.8–31.5) 0.11
Weight (kg) 94.2 (15.4) 91.3 (13.6) 0.42
BMI (kg/m2) 33.3 (5.1) 33.3 (4.6) 0.98
Waist (cm) 102.6 (10.8) 102.6 (11.1) 0.99
Waist/hip ratio 0.91 (0.08) 0.92 (0.10) 0.75
Systolic BP (mmHg)/diastolic BP 
(mmHg)
123 (9)/79 (8) 124 (9)/80 (7) 0.55/0.75
Smoking (<10 cigarettes/day) 18.8% (9) 33.3% (8) 0.24
First degree relative with diabetes 31.3% (15) 26.1% (6) (n=23) 0.78
Ethnicity   0.68
Caucasian 93.8% (45) 91.7% (22)  
Rotterdam phenotype   0.54
O/A + HA + PCO 39.6% (19) 45.8% (11)  
O/A + HA 2.1% (1) 8.3% (2)  
HA + PCO 22.9% (11) 16.7% (4)  
O/A + PCO 35.4% (17) 29.2% (7)  
Ferriman Gallway score 7.0 (3.0–11.5) 7.0 (2.5–12.5) 0.90
Total testosterone (nmol/L) 1.23 (0.91–1.63) 1.35 (0.95–1.93) 0.46
SHBG (nmol/L) 31.0 (22.0–44.5) 30.5 (23.0–37.5) 0.68
Total cholesterol (mmol/L) 4.61 (0.80) 4.67 (0.57) 0.75
LDL cholesterol (mmol/L) 2.83 (0.71) 2.99 (0.54) 0.30
HDL cholesterol (mmol/L) 1.14 (0.25) 1.09 (0.28) 0.40
Triglycerides (mmol/L) 1.23 (0.90–1.63) 1.15 (0.90–1.47) 0.64
HbA1c (mmol/mol) 34.2 (2.8) 34.6 (3.4) 0.66
HOMA2-IR 2.29 (1.83–2.84) 2.42 (1.91–3.20) 0.25
GFR (mL/min/1.73 m2) 112.8 (13.3) 117.5 (9.7) 0.12
Values are presented as mean (s.d.), median (p25–p75).
Between-group differences at baseline were determined by un-paired t-test, Mann Whitney U-test, Chi2-test and Fisher exact test as appropriate.
BMI, body mass index; BP, blood pressure; O/A, oligo-/amenorrhea; HA, hyperandrogenism; PCO, polycystic ovaries; SHBG, sex hormone binding globulin; 
LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1c, glycated hemoglobin; HOMA2-IR, homeostasis model assessment-estimated insulin 
resistance; GFR, glomerular filtration rate.
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Anthropometric and metabolic measurements
Mean weight, BMI and waist circumference decreased 
significantly in the liraglutide group compared with the 
placebo group, −5.2 kg (95% CI −7.5 to −3.0, P < 0.0001), 
−1.8 kg/m2 (95% CI −2.7 to −1.0, P < 0.0001) and −5.7 cm 
(95% CI −9.3 to −1.9, P < 0.05), respectively. When 
compared to placebo, there was no effect of liraglutide on 
HOMA2-IR or on triglyceride and cholesterol levels (data 
not shown).
Thrombin generation, vWF, PAI-1 and hsCRP
In the liraglutide group, peak thrombin concentration 
decreased by −16.71 nmol/L (95% CI −31.11 to −2.32, 
P < 0.05) and lag time and time to peak increased by 
0.13 min (95% CI 0.01–0.25, P < 0.05) and 0.38 min (95% 
CI 0.09–0.68, P < 0.05), respectively (Fig.  2). There was 
no effect on the primary outcome ETP (Table 3). Levels 
of PAI-1 decreased 12% (95% CI 0–23, P = 0.05) over six 
months in the liraglutide group, and there was a trend 
toward decreased PAI-1 in the liraglutide group when 
compared with the placebo group (P = 0.10, Fig.  3). We 
observed no differences between subgroups with regard 
to effect on thrombin generation, vWF, PAI-1 or hsCRP 
levels.
Associations between ETP and anthropometric, 
metabolic and endocrine variables
At baseline, ETP levels were associated with anthropometric 
and metabolic variables: BMI, waist circumference, 
diastolic blood pressure, HOMA2-IR, triglycerides, hsCRP 
and PAI-1, and reciprocally associated with HDL and 
SHBG. Including BMI in the model, only levels of PAI-1 
remained associated with ETP. Including HOMA2-IR, 
triglycerides and hsCRP in the model, this association was 
no longer statistically significant.
Discussion
In this placebo-controlled randomized trial, investigating 
the effect of 26-week liraglutide intervention on VTE and 
CVD risk markers in overweight women with PCOS, we 
found a mean weight loss of 5.2 kg. Concomitantly, we 
observed significant improvements in thrombin generation 
parameters: decreased peak thrombin concentration, 
Table 2 Adverse effects during 26 weeks liraglutide or placebo treatment.
 Liraglutide (n = 47) Placebo (n=23) P
Nausea 78.7 (37) 13.0 (3) <0.01
Vomiting 10.6 (5) 0 (0) 0.2
Ructus/heartburn 17.0 (8) 0 (0) 0.05
Diarrhea 10.6 (5) 4.4 (1) 0.7 
Constipation 25.5 (12) 0 (0) <0.01
Gastroenteritis 10.6 (5) 8.7 (2) 1.0
Epigastrial pain 17.0 (8) 0 (0) 0.05
Gallstone related pain 6.4 (3) 4.4 (1) 1.0
Cholecystectomy 4.3 (2) 0 (0) 1.0
Hypotension 2.1 (1) 0 (0) 1.0
Tachycardia 2.1 (1) 0 (0) 1.0
Syncope 2.1 (1) 0 (0) 1.0
Dizziness 8.5 (4) 0 (0) 0.3
Headache 0 (0) 13.0 (3) <0.05
Upper respiratory tract infection 14.9 (7) 17.4 (4) 1.0
Urinary tract infection 4.3 (2) 0 (0) 1.0
Hair loss 2.1 (1) 0 (0) 1.0
Rash at injection site 6.4 (3) 0 (0) 0.6
Joint pain 2.1 (1) 0 (0) 1.0
Values are presented as % (n). Bold indicates P < 0.05. Adverse effects experienced at any point of the study period. Between-group differences were 
determined using Fishers exact test.
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increased lag time and time to peak. However, the changes 
observed was not statically significant when compared 
with placebo, and liraglutide intervention appeared 
insufficient to influence the primary outcome, the total 
endogenous thrombin potential (ETP) in our population. 
In the liraglutide group, we demonstrated reduced PAI-1 
levels and a trend toward a between-group difference, 
indicating improved fibrinolytic potential, and thus, a net 
beneficial effect on validated markers of VTE and CVD risk.
To our knowledge, no previous studies have focused 
on the effect of liraglutide on thrombin generation. 
An open-label, single-arm study investigating the 
effect of liraglutide (1.8 mg/day for six months) in 36 
obese women with and without PCOS found improved 
endothelial function, seen as reduced levels of cell 
adhesion markers as well as slightly reduced clot lysis area, 
a complex measure of clot formation, density and lysis 
potential (29). Discrepancies might be explained by the 
single-armed design and their population having higher 
BMI and worse metabolic profile than ours. Moreover, 
clot formation is a measurement of platelet function and 
fibrin production, depending on thrombin concentration 
among numerous other factors (36), which is why our 
studies are not directly comparable.
Figure 2
Change in thrombin generation parameters after 
intervention with liraglutide or placebo for 
26 weeks. Dots represent mean change from 
baseline to follow-up in the liraglutide group and 
squares represent mean change from baseline to 
follow-up in the placebo group. Data are 
presented as mean (95% CI). Within-group 
comparisons demonstrated decreased peak 
thrombin concentration (top right), increased 
time to peak (bottom left) and increased lag time 
(bottom right), *P < 0.05. NS, non-significant.
Table 3 Changes in pro-thrombotic and pro-inflammatory biomarkers from baseline to 26-week follow-up.
   
Liraglutide
 
Placebo
Difference between 
groups
 
Baseline (n = 48)
Difference at 
six months 
(n = 44) P Baseline (n=24)
Difference at six 
months (n=21) P
Mixed models 
(crude) P
ETP 
(µmol/L × min)
1796  
(332)
−57.6  
(−132.3 to 17.2)
0.13 1830  
(285)
−8.2  
(−98.7 to 82.3)
0.85 −47.3  
(−161.9 to 67.3)
0.41
Peak thrombin 
(nmol/L)
247.3  
(41.1)
−16.7  
(−31.1 to 2.3)
<0.05 245.7  
(46.5)
−3.3  
(−22.9 to 16.3)
0.73 −12.6  
(−35.5 to 10.3)
0.27
Time to peak 
(min)
7.36  
(1.11)
0.38  
(0.09–0.68)
<0.05 7.86  
(1.19)
0.12  
(−0.30 to 0.54)
0.56 0.25  
(−0.25 to 0.75)
0.32
Lag-time (min) 3.33  
(2.92–3.67)
0.13  
(0.01–0.25)
<0.05 3.59  
(3.00–3.84)
0.09  
(−0.09 to 0.26)
0.32 0.04  
(−0.17 to 0.24)
0.72
vWF (% of 
normal)
99.5  
(87.5–122.5)
1.64  
(−3.3 to 6.6)
0.51 123.0  
(92.0–145.0)
−5.2  
(−12.1 to 1.7)
0.13 1.03  
(0.96–1.11)a
0.35
hsCRP (mg/L)b 2.05 (0.79–3.65) 0.85  
(0.70–1.03)a
0.09 3.48  
(1.17–4.32)
0.75  
(0.43–1.30)a
0.29 1.02  
(0.67–1.55)a
0.92 
Values are presented as mean (s.d.), median (p25–p75) and differences as mean (95%CI) or aratio from logarithmic transformed numbers. Bold indicates 
P < 0.05. Adjusting the mixed model for age, BMI and smoking at baseline did not alter the results significantly.
bliraglutide n = 45 (baseline), n = 42 (follow-up), placebo n = 20 (baseline), n = 18 (follow-up).
ETP, endogenous thrombin potential; PAI-1, plasminogen activator inhibitor 1; hsCRP, high sensitivity C-reactive protein and vWF = von Willebrand factor.
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Glintborg and coworkers recently studied the effect 
of metformin and combined oral contraceptives (COC) 
on thrombin generation in a RCT with 90 PCOS women 
(12). Thrombin generation, measured as ETP and peak 
thrombin concentration, increased after 12  months 
of intervention with COC, as well as with combined 
treatment (COC + metformin), but no changes were 
seen in the metformin-alone group despite an almost 
significant median weight loss of 3 kg (37). The increase 
in thrombin generation was smaller in the combined 
group compared with that in the COC group, suggesting 
a protective effect of metformin. Except from lower mean 
BMI, their population was comparable to ours and the 
same thrombin generation assay was used.
Our hypothesis of weight loss and improved glycemic 
control resulting in reduced thrombin generation has 
been confirmed in other populations. Bariatric surgery 
in 36 morbidly obese adults (with and without type 2 
diabetes) resulted in weight loss (mean −32%), reduced 
insulin resistance as well as decreased ETP and peak 
thrombin concentration at two-year follow-up (21). 
Additionally, one year of lifestyle intervention in 27 
overweight children caused reduced BMI as well as 
decreased ETP and peak thrombin concentration (22). 
In a RCT, Gram and coworkers found three months of 
daily endurance exercise to reduce BMI and ETP in 53 
healthy, moderately overweight, young men, whereas 
there was no effect on peak thrombin concentration (23). 
Reasons for disagreement between our findings and the 
mentioned studies might be the excessive weight loss in 
the first (21), the lack of control group in the first and 
second (21, 22) and possibly a ‘healthier’ weight loss in 
the latter (23).
Intervention with GLP-1 analogs has previously been 
shown to affect the metabolic parameters in PCOS. In 
several smaller trials on women with PCOS, GLP-1 analogs 
were found to reduce well-known risk factors of CVD: 
body weight, waist circumference and visceral adipose 
tissue (28, 31, 32), whereas results regarding HOMA-IR 
are conflicting (28, 29, 30) and results on hsCRP are 
sparse and inconsistent (28, 29). In PCOS, metformin 
seems to attenuate endothelial dysfunction and low-
grade inflammation, evaluated as levels of PAI-1 and 
hsCRP (24, 38, 39, 40). However, results are conflicting 
(41), and most of the studies are single-armed or open-
labeled, testing metformin vs COC. Physical exercise was 
found to reduce BMI as well as levels of PAI-1 and hsCRP 
compared to baseline in a six-month RCT on 136 women 
with PCOS (42). However, the effect disappeared when 
compared with placebo or COC (42). Also, a lifestyle-
induced weight loss of 8–11% was found to cause reduced 
levels of PAI-1 in an obese PCOS population (43). As most 
interventional studies on endothelial function and low-
grade inflammation in PCOS lack a placebo arm, we 
cannot easily compare our findings.
Possibly GLP-1 analogs influence hemostasis in a 
direct way. The effect of GLP-1 analogs on hemostasis 
has been studied in vitro and in animal models. Human 
megakaryocytes have been found to express GLP-1 
receptors and both human and murine blood incubated 
with the GLP-1 analog exenatide have been found to 
have reduced in vitro thrombus formation (44). Arterial 
thrombus formation decreased in mice treated with i.v. 
exenatide, suggesting GLP-1 analogs to reduce platelet 
aggregation by inhibiting the release of α- and dense 
granules (44). Moreover, liraglutide has been shown to 
attenuate high-glucose-mediated PAI-1 expression in 
human endothelial cells (45).
The anti-atherothrombotic potential of GLP-1-based 
therapies has been studied both in type 2 diabetes and 
obesity and have been found to reduce the levels of 
hsCRP and PAI-1 in both conditions (26, 27). In the recent 
LEADER trial including more than 9000 patients with type 
2 diabetes and a concomitant cardiovascular condition, 
liraglutide reduced the occurrence of CVD events and the 
rate of CVD death, as compared with placebo, as an add-on 
medication (46). The LEADER population was large and 
therefore at considerably greater risk of CVD events than 
our, younger, population still being relatively healthy 
with regard to having obtained a major cardiovascular 
burden.
This study has several strengths: the placebo-controlled 
RCT design, the high external validity and the low 
dropout rate. However, there are some limitations. Only 
83% of the women in the liraglutide group completed the 
Figure 3
Levels of PAI-1 at baseline and 26-week follow-up. Open circles represent 
the liraglutide group and black squares the placebo group. Data are 
presented as median (p25–p75) at baseline and follow-up. There was a 
trend toward decreased PAI-1 in the liraglutide group as compared with 
the placebo group, 16% (95% CI −4 to 32, P = 0.10). *P = 0.05. NS, 
non-significant; PAI-1, plasminogen activator inhibitor-1.
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several smaller trials on women with PCOS, GLP-1 analogs 
were found to reduce well-known risk factors of CVD: 
body weight, waist circumference and visceral adipose 
tissue (28, 31, 32), whereas results regarding HOMA-IR 
are conflicting (28, 29, 30) and results on hsCRP are 
sparse and inconsistent (28, 29). In PCOS, metformin 
seems to attenuate endothelial dysfunction and low-
grade inflammation, evaluated as levels of PAI-1 and 
hsCRP (24, 38, 39, 40). However, results are conflicting 
(41), and most of the studies are single-armed or open-
labeled, testing metformin vs COC. Physical exercise was 
found to reduce BMI as well as levels of PAI-1 and hsCRP 
compared to baseline in a six-month RCT on 136 women 
with PCOS (42). However, the effect disappeared when 
compared with placebo or COC (42). Also, a lifestyle-
induced weight loss of 8–11% was found to cause reduced 
levels of PAI-1 in an obese PCOS population (43). As most 
interventional studies on endothelial function and low-
grade inflammation in PCOS lack a placebo arm, we 
cannot easily compare our findings.
Possibly GLP-1 analogs influence hemostasis in a 
direct way. The effect of GLP-1 analogs on hemostasis 
has been studied in vitro and in animal models. Human 
megakaryocytes have been found to express GLP-1 
receptors and both human and murine blood incubated 
with the GLP-1 analog exenatide have been found to 
have reduced in vitro thrombus formation (44). Arterial 
thrombus formation decreased in mice treated with i.v. 
exenatide, suggesting GLP-1 analogs to reduce platelet 
aggregation by inhibiting the release of α- and dense 
granules (44). Moreover, liraglutide has been shown to 
attenuate high-glucose-mediated PAI-1 expression in 
human endothelial cells (45).
The anti-atherothrombotic potential of GLP-1-based 
therapies has been studied both in type 2 diabetes and 
obesity and have been found to reduce the levels of 
hsCRP and PAI-1 in both conditions (26, 27). In the recent 
LEADER trial including more than 9000 patients with type 
2 diabetes and a concomitant cardiovascular condition, 
liraglutide reduced the occurrence of CVD events and the 
rate of CVD death, as compared with placebo, as an add-on 
medication (46). The LEADER population was large and 
therefore at considerably greater risk of CVD events than 
our, younger, population still being relatively healthy 
with regard to having obtained a major cardiovascular 
burden.
This study has several strengths: the placebo-controlled 
RCT design, the high external validity and the low 
dropout rate. However, there are some limitations. Only 
83% of the women in the liraglutide group completed the 
study at the intended dose (1.8 mg/day). An explanation 
for finding unaltered thrombin generation and levels of 
hsCRP and vWF with liraglutide therapy could be that 
our population was relatively ‘metabolically healthy’. 
Worth noting is that the baseline  fasting glucose and 
lipid levels were within normal range, despite the high 
mean BMI (33 kg/m2) and waist circumference (103 cm). 
Inclusion of women being at a higher risk of CVD, i.e., 
with even higher BMI, reduced glucose tolerance, overt 
diabetes or dyslipidemia, might have given different 
results. This might also have been obtained by using 
the National Institutes of Health criteria instead of the 
Rotterdam criteria (3) and including older women. Our 
lack of findings might be due to lack of power. The fact 
that some of the TGT parameters were altered in the 
liraglutide group indicates that there may be an effect of 
the treatment, but the population might be too small to 
identify it. Also, when looking at the CIs, we can neither 
confirm nor rule out a beneficial effect of liraglutide on 
thrombin generation.
In conclusion, in an overweight PCOS population, 
26 weeks of liraglutide intervention caused minor 
alterations in thrombin generation parameters, but 
no difference in overall thrombin generation when 
compared to placebo. We observed a substantial weight 
loss and a trend toward improved fibrinolytic potential. 
Taken together, the results point toward beneficial effects 
on markers of VTE and CVD risk, which are promising, 
but need to be corroborated in larger studies. Liraglutide 
was well tolerated, although one should be aware of the 
risk of weight loss-related gallbladder stone attacks in a 
population of young overweight women.
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